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Abstract
Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and 
immune-targeted drugs that have transformed outcomes for some malignancies.1 Tumor 
complexity and heterogeneity suggest that the “precision medicine” paradigm of cancer therapy 
requires treatment to be personalized to the individual patient.2–6 To date, precision oncology trials 
have been based upon molecular matching with predetermined monotherapies.7–14 Several of 
these trials have been hindered by very low matching rates, often in the 5–10% range,15 and low 
response rates. Low matching rates may be due to the use of limited gene panels, restrictive 
molecular matching algorithms, lack of drug availability or the deterioration and death of end-
stage patients before therapy can be implemented. We hypothesized that personalized treatment 
with combination therapies would improve outcomes in patients with refractory malignancies. As 
a first test of this concept, we implemented a cross-institutional, prospective study (I-PREDICT, 
NCT02534675) that used tumor DNA sequencing and timely recommendations for individualized 
treatment with combination therapies. We found that administration of customized multi-drug 
regimens was feasible, with 49% of consented patients receiving personalized treatment. Targeting 
of a larger fraction of identified molecular alterations, yielding a higher “matching score,” was 
correlated with significantly improved disease control rates, as well as longer progression-free and 
overall survival rates, as compared to when fewer somatic alterations were targeted. Our findings 
suggest that the current clinical trial paradigm for precision oncology, which pairs one driver 
mutation with one drug, may be optimized by treating molecularly complex and heterogeneous 
cancers with combinations of customized agents.
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We conducted Investigation of Profile-Related Evidence Determining Individualized Cancer 
Therapy (I-PREDICT, NCT02534675), a prospective navigation trial, at two centers 
(University of California, San Diego Moores Cancer Center and Avera Cancer Institute). 
Tissue genomic profiling using next generation sequencing (NGS) (Foundation Medicine; 
236–405 genes), and, if possible, PD-L1 immunohistochemistry (IHC), tumor mutational 
burden (TMB), microsatellite instability (MSI) status, and NGS of blood-derived circulating 
tumor DNA (ctDNA) were performed. Based on this information, a Molecular Tumor Board 
consisting of oncologists, pharmacologists, cancer biologists, geneticists, surgeons, 
radiologists, pathologists, and bioinformatics experts focused on selecting customized, 
multi-drug combinations to target a majority of the genomic alterations in each patient’s 
tumor(s) while simultaneously considering potential overlapping drug toxicities. The 
therapies ultimately administered were based on the treating oncologists’ choice, with 
physicians crafting the regimen by incorporating Molecular Tumor Board discussions, as 
well as patient preference, attention to co-morbidities, consideration of drug toxicities, 
insurance payor coverage of off-label agent(s), and investigational agent clinical trial 
availability, hence reflecting actual clinical practice in the United States today.
One hundred and forty-nine patients with previously treated, refractory, lethal metastatic 
cancers (Stage IV disease) were consented to the I-PREDICT trial. Eighty-three patients 
(56%) were treated and evaluable for analysis (Supplementary Table 1 and Supplementary 
Table 2). These 83 patients had a median of two prior lines of therapy. The other 66 patients 
were considered inevaluable, mainly because they deteriorated or died before treatment 
could be initiated (Extended Data Figure 1). Patient demographics of the 83 treated patients 
are described in Table 1. The most common primary tumor sites were gastrointestinal 
(including hepatopancreatobiliary) (42.2%), gynecologic (16.9%), breast (14.5%), and 
central nervous system (CNS, 7.2%). The median number of characterized genomic 
alterations per tumor was 5 (range: 1–20; Table 1).
Of the 83 treated patients, 73 (88% of treated patients; 49% of enrolled patients) were 
administered a personalized, precision therapy consisting of ≥1 molecularly “matched” 
treatments (≥1 MT), following receipt of molecular profile results. No two molecular 
profiles were identical and, hence, most treatment regimens were not exactly alike. The 
other 10 patients (12%) were not administered matched therapies (no-MT), although 9 of 
them had potential matches for receiving targeted therapies. Instead, they received only 
“unmatched” standard-of-care drugs for their respective tumor types, most often due to the 
treating oncologists’ choices (36.4%), patient preference (36.4%), clinical trial availability 
of other investigational agents (18.2%), and consideration of drug toxicities (9.1%) 
(Supplementary Table 3). The median time from study consent to treatment initiation was 
less than one month (0.93 months, 95% CI 0.73–1.4). Since the protocol permitted use of 
FoundationOne molecular tests performed as part of physicians’ routine practice (before 
enrollment), the median time from molecular results until treatment initiation was 2.0 
months (95% CI 1.3–2.3).
The 73 patients (≥1 MT) had previously been treated with a median of 2 (IQR 1–3) prior 
lines of therapy. They received a median of 2 drugs in their on-study treatment regimens 
(range: 1–5, Table 1). Figure 1A–B details the percentage of matched genomic alterations in 
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a pathway, complex, or gene that were targeted by the customized therapeutic regimens 
(median of 2 genomic alterations targeted per patient; range: 1–6). Of the 73 patients, all had 
matches linked to genomic alterations (see Supplementary Table 2 for molecular results and 
drug matches with supporting references); in 67 patients (91.8%), the drugs were gene 
product-targeted drugs, while the others were checkpoint inhibitor immunotherapy, based on 
the genomic profile (Supplementary Table 4). Specifically, a checkpoint inhibitor was 
administered (alone or in combination with other drugs) to 14 matched patients (19.1%) 
based upon PD-L1 IHC positivity, high/intermediate TMB, MSI high status, CD274 (PD-
L1) amplification, or when tumors had ≥8 genomic alterations with unknown PD-L1 IHC, 
TMB, and MSI.16–18 Four patients (5.5%) were treated with hormone therapies in 
combination with other molecularly targeted drugs based on positive hormone status. Only 
two patients had one genomic alteration and were molecularly matched to one drug. Patients 
given no-MT (N=10) received a median of 2 drugs (range: 1–3).
As previously described,9,11 a “Matching Score” score system was then utilized for each 
patient. Blinded to patient outcomes, the investigators calculated the total number of 
molecular alterations matched to the drugs administered and divided that number by the total 
number of characterized genomic aberrations. Further details for scoring are delineated in 
the Methods (Matching Score).19–24 We next stratified patients based upon Matching 
Scores >50% (designated as high; N=28 patients) versus ≤50% [designated as low; N=55 
patients including 10 patients with no-MT administered (Matching Scores = 0%)] 
(Supplementary Table 1).19 The total number of molecular matches for the high group was 
67 (mean: 2.4 matches per patient). Patients with high Matching Scores received a median of 
2 drugs in their regimen (range: 1–5 drugs) as did patients with low Matching Scores 
(median: 2 drugs (range: 1–4 drugs)(Supplementary Table 2 and Supplementary Table 4).
Patients were followed until progression of disease, treatment intolerability, or death. The 
overall median follow up was 10.8 months (95% CI 6.9–14.6; Supplementary Table 5). 
Overall, 30% of patients evaluable for response achieved disease control [defined as stable 
disease (SD) ≥6 months (N=4); complete response (CR, N=1); or partial response (PR, 
N=16)]. When patients were stratified to high and low groups, a high Matching Score was an 
independent predictor of an increased disease control rate (DCR); 50% of the patients with a 
high Matching Score achieved disease control as compared to 22.4% of patients with a low 
Matching Score (P=0.028, Table 2). Amongst the different variables tested, Matching Score 
>50% was the only parameter significantly associated with higher DCR (Table 2 and Figure 
1C). The multivariable analysis confirmed that only a high Matching Score was an 
independent predictor of higher DCR [odds ratio (OR) 3.6; 95% CI 1.1–11.8; P=0.033].
A higher Matching Score was also an independent predictor of longer progression-free 
survival (PFS) (Table 2 and Figure 1E) and overall survival (OS) (Table 2 and Figure 1F) 
according to Kaplan-Meier analysis20. All treated patients (N=83) were included in the PFS 
and OS analyses of high Matching Score versus low Matching Score (median PFS: 6.5 
versus 3.1 months, P=0.001; median OS: not reached after a median follow up of 8.5 months 
versus 10.2 months; P=0.046). In multivariable Cox regression models adjusting for patient 
age, gender, matching score, disease site, combination therapy, and therapy line, a high 
Matching Score remained the most significant variable associated with a prolonged PFS [HR 
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for low versus high Matching Score: 0.34 (95% CI 0.19–0.62, P=0.0004)] and with a 
prolonged OS [HR for low versus high Matching Score: 0.42 (95% CI 0.18–0.95, P=0.038)].
Generally, PFS becomes shorter with each line of therapy administered. Thus, we compared 
the PFS on the study (PFS2) with the immediate prior line of unmatched therapy (PFS1), 
hence using the patient as their own control. Specifically, we compared the frequency of 
patients with a PFS ratio (PFS2/PFS1) ≥1.3, based upon the work of Von Hoff and 
colleagues who reported that 27% (18 of 66) of molecularly matched patients had a PFS 
ratio of ≥1.3.7 In the current study, a high Matching Score was the only parameter 
significantly impacting the PFS ratio ≥1.3 in both the univariable (P=0.026) and 
multivariable analyses (P=0.015) (Table 3 and Figure 1D). Indeed, 75% of patients reached a 
PFS ratio ≥1.3 if the Matching Score was >50% as compared to 36.6% if the Matching 
Score was ≤50% (P=0.026) (Figure 1D). These findings indicate PFS can be prolonged by 
30% or longer in later lines of therapy when a majority of the molecular alterations are 
targeted.
We also attempted to understand if other parameters were impacting patient outcomes in a 
sub-analysis that only included patients who received ≥1 MT (N=73) (Supplementary Table 
6). This sub-analysis demonstrated that both a time interval between the tissue biopsy and 
molecularly matched treatment initiation of <9 months, as well as the addition of 
chemotherapy in the regimen, increased the rate of patients achieving disease control (SD≥6 
months/CR/PR) in a multivariate analysis (P=0.031 and P=0.033, respectively). However, 
only the Matching Score remained a favorable independent predictor in the multivariable 
analysis for the PFS and OS analyses (P=0.004 and P=0.050, respectively), further 
validating earlier studies of this methodology.9,11
We also evaluated the role of targeting downstream of RAS and TP53, two common 
mutations in cancers (Figure 1A–B). To date, there is not a specific drug known to directly 
target RAS. Furthermore, the efficacy of MEK inhibitors has been circumstantial and mixed.
25
 It is unclear if the weak efficacy of current MEK inhibitors for KRAS targeting is a 
fundamental property of these inhibitors or if it is related to the fact that KRAS alterations 
are usually accompanied by other drivers that need to be targeted. Of interest in this regard is 
a recent report demonstrating that a patient with Rosai Dorfman syndrome and a single 
activating KRAS alteration had a remarkable response to the MEK inhibitor cobimetinib.26 
In regard to TP53 aberrations, recent data suggest it may be indirectly/partially target 
matched with VEGF/VEGFR inhibitors inhibitors (perhaps because loss of p53 function is 
associated with upregulation of VEGF-A).27,28 Thus, we evaluated the DCR, PFS, and OS 
for patients with TP53 and/or RAS mutations that were treated with VEGF/VEGFR and/or 
MEK inhibitors versus patients with TP53 and/or RAS mutations who were not matched to 
any therapy (Supplementary Table 7). There is no difference between the groups, although 
the numbers are too small to draw definitive conclusions. However, Wheler and colleagues 
did address this question in regard to TP53 alterations matched to VEGF/VEGFR inhibitors.
27
 That report showed that VEGF/VEGFR inhibitor therapy was independently associated 
with improvement in all outcome parameters for TP53-mutant patients (but not for TP53 
wild-type patients) (who received no other molecular-matched agents) treated with VEGF/
VEGFR inhibitors (versus those not treated with these agents).
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Overall, 16 of 83 treated patients (19.3%) experienced ≥1 serious adverse events (SAE) in 
the study [14 of 73 (19.2%) with ≥1 MT and 2 of 10 (20%) with no MT administered]. The 
number of drugs in the regimen was unrelated to the number of SAEs. The SAEs deemed at 
least possibly or probably related to drug trended to be less common in patients with a 
Matching Score >50% versus ≤50% [1 (3.6%) versus 7 (15.6%); P=0.14] There were no 
treatment-related deaths in this study. Taken together, therapy-related SAEs tended to be 
more common in the patients who received no-MT and in patients with a Matching Score 
≤50%. (Supplementary Tables 8–10).
Matching single agents (other than immunotherapies for select individuals) to tumors with 
multiple genomic alterations is unlikely to result in prolonged or complete remissions. In 
fact, only two patients (2.7%) in our cohort with ≥1 MT had only one genomic alteration 
identified. Yet, precision medicine trials performed to date concentrate on finding 
commonalities between patients and then matching them to monotherapy, a design 
consistent with traditional treatment models, but inconsistent with the reality unveiled by 
genomics (i.e., the vast majority of patients with metastatic tumors have numerous genomic 
alterations that differ from patient to patient).2–6
We achieved a matching rate of 49% (73 of 149 patients), a number considerably higher than 
in any other precision medicine trials of which we are aware. This high matching rate was 
based on several key factors: (i) molecular interrogation by NGS for a large panel of cancer-
related genes, and including assessment, when possible, of TMB, MSI status, PD-L1 IHC 
and ctDNA; (ii) timely Molecular Tumor Board discussions (that occurred immediately 
upon receipt of molecular results including by ad hoc e-meetings) to inform treatment 
recommendations without delay; and (iii) use of a medication acquisition specialist and 
clinical trials coordinator to ensure rapid access to drugs. It is important to note that we did 
not treat canonical tumor types for success. For example, no melanomas were treated and 
only three lung cancers (3.6%) were included, demonstrating that this approach may be 
feasible and effective in diseases that are classically not thought of in the setting of 
molecularly targeted approaches.
The study had several limitations, including the lack of a control group. In addition, the 
number of alterations detected may depend upon the number of genes interrogated in a given 
panel test. Therefore, the specific Matching Scores and cut offs could differ between panels. 
However, the more comprehensive the panel with regard to cancer-related genes, the more 
accurate the Matching Score should be. Further, the important finding herein is that higher 
degrees of matching are associated with better outcomes than lower degrees of matching, 
and that higher Matching Scores often require customized combinations, rather than single 
agents, as is often given in traditional precision oncology trials. Further validation and assay 
harmonization studies will be needed to determine a universal cut off for matching, although 
it remains conceivable that degrees of matching and outcome are related in a continuum. 
Another limitation relates to the fact that some of the matches, especially in the high 
Matching Score group, were to immunotherapy and this was often based upon high TMB 
status. Hence, these results may confound our ability to calculate matching of strictly gene-
targeted agents. But, our findings demonstrate that genomics and other biomarkers are more 
broadly useful for matching a variety of drugs beyond gene-targeted agents. However, our 
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findings may have potential self-selection bias for patients that sought out enrollment on the 
trial or bias based upon physician referral. Even so, this study represents real-world practice 
patterns, and the molecular matching of targets with cognate agents is generally independent 
of these issues and therefore likely to have low impact on the results. Finally, a limitation of 
the paper is the small number of patients in individual subgroups, such as those with TP53 
alterations matched with VEGF/VEGFR inhibitors or RAS mutations matched with MEK 
inhibitors alone, which precluded determining the efficacy of these matches when not part of 
a combination regimen. Additional studies with larger sample size are needed.
In conclusion, the administration of N-of-1 customized, multi-drug combinations targeting 
multiple identified molecular alterations (discerned by NGS) based upon recommendations 
from a just-in-time Molecular Tumor Board was feasible and safe. Characteristics of this 
intervention (e.g., the Matching Score) were associated with significant improvements in the 
disease control rate and all survival parameters. Though we were able to administer ≥1 
matched drug to 49% of our patients, substantial numbers of patients still dropped off, 
mostly due to disease deterioration with hospice placement or demise. Therefore, 
personalized, precision medicine approaches should be instituted earlier in the course of the 
disease. At present, there is another study group in the I-PREDICT trial investigating the 
administration of customized combination therapies in treatment-naïve patients with 
unresectable and metastatic disease.29 Enrollment is ongoing. Taken together, our findings 
underscore the safety, feasibility and the importance of designing precision oncology trials 
that emphasize personalized, individually tailored combination therapies, rather than 
scripted monotherapies, for patients with lethal cancers. Follow up studies with greater 
numbers of patients are needed to confirm our findings.
METHODS
Human Research
Ethics Committee: The Investigation of Profile-Related Evidence Determining 
Individualized Cancer Therapy (I-PREDICT) was reviewed and approved by the UC San 
Diego Protocol Review and Monitoring Committee (PRMC) and the Human Research 
Protections Program (HRRP)/Institutional Review Board (IRB) (Protocol 141758). It was 
subsequently reviewed and approved by the Avera Cancer Institute PRMC and IRB 
(Protocol 2015.058). The safety of the protocol was also monitored by the UC San Diego 
Moores Cancer Center Data Safety Monitoring Board (DSMB).
Ethical Compliance: During the preparation, submission, conduct, and analysis of this 
study, we complied with all relevant ethical regulations.
Informed Consent: All patients enrolled on the I-PREDICT (NCT02534675) study 
underwent informed consent in their native languages via licensed medical interpreters, as 
well as signed consented forms in their native languages. Patients who were navigated to an 
investigational drug or drug(s) that were part of an investigational study signed consent for 
that study as well.
Sicklick et al. Page 7
Nat Med. Author manuscript; available in PMC 2019 October 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Study Design
This was a prospective, open label navigational investigation to evaluate the feasibility of 
using molecular profile-based evidence to determine individualized cancer therapy for 
patients with incurable malignancies. This was a non-randomized, histology-agnostic trial. 
Although there would be a case mix of histologies, we know that individual histologies are 
composed of a heterogeneous mix of genomic alterations. It is not clear that one case mix is 
better or worse than another. Thus, we designed the study to test a strategy of molecular 
matching that may apply across cancers.
Sample size: This feasibility study has descriptive primary analyses to characterize the 
study findings. There were three groups and only results from Group 3 (previously treated 
unresectable/metastatic patients) are described herein; groups 1 and 2 (treatment-naïve 
unresectable and treatment-naïve metastatic with lethal diseases) are not described and are 
accruing. A Molecular Tumor Board recommended therapy, but treatment decisions were the 
choice of the physician. The primary study objective was to determine the feasibility of 
using molecular testing to determine therapy for patients with previously treated cancers 
with incurable biology (≥50% 2- year cancer-associated mortality). Primary and secondary 
endpoints included: the proportion of patients who receive molecularly targeted matched 
treatment after recommendations based on genomic analysis (primary endpoint); proportion 
of patients with actionable genomic alterations and overall response rate, regression rate, 
progression-free and overall survival and incidence of high-grade adverse events (secondary 
and exploratory endpoints). Relevant hypotheses included: patients who receive targeted 
therapy based upon recommendations from actionable genomic alteration(s) will yield anti-
tumor activity; the PFS on matched therapy will be greater than on their last unmatched 
therapy. For evaluation of treatment decisions, the Study Committee assessed the degree of 
matching that occurred using the best information available at the time of the data 
evaluation. The original plan was to enroll 75 evaluable patients. Since this was a 
hypothesis-generating, descriptive trial, this number was later expanded to permit enrollment 
of up to 1,000 patients. Based on the fact that a minority of patients is usually matched to 
therapy on precision medicine trials, it was expected that we would show feasibility with 
40% of the 75 evaluable patients (N=30) being matched and 60% treated with no matched 
therapy (N=45). With the sample size of 30 matched versus 45 unmatched, we would have 
79% power to detect a response rate of 0.25 versus 0.05 in the two arms with one-sided 10% 
type I error rate using the continuity corrected chi-square test. We calculated we would have 
more than 80% power to detect the difference between the two groups using the log-rank test 
when the median PFS is 4 months and 2 months for the two arms, respectively. We analyzed 
group 3 after enrollment of 149 patients; feasibility to administer matched therapy was 
confirmed because, of the 83 evaluable treated patients, 73 (88% of evaluable treated 
patients and 49% of enrolled patients) were matched. The ability to compare matched and 
unmatched patient was limited by the small number of evaluable unmatched patients 
(N=10). As part of the descriptive analysis, we evaluated the effect of degree of matching in 
patients with low versus high matching scores (N=55 versus 28 patients).
Early safety stopping rule: Simon’s two-stage design was used. The null hypothesis was 
that the true response rate is 0.05 and this would be tested against a one-sided alternative. In 
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the first stage, 13 patients would be accrued. If there were 0 responses in these 13 patients, 
the study would be stopped. Other early stopping rules were for >10 drug related severe 
adverse events and >10 drug-related Grade 4–5 toxicities. Early stopping was not triggered 
in the study.
Data Exclusion: No data were excluded from analysis.
Replication: As this is a clinical trial, no replication was possible or performed.
Patients
We analyzed the clinicopathologic and outcomes data of 149 patients with previously treated 
advanced or metastatic solid malignancies who consented to the I-PREDICT study (Group 
3) during the study period. The study was activated on February 13, 2015. Accrual is 
ongoing in Groups 1 and 2 [patients with treatment-naïve unresectable (Group 1) or 
metastatic (Group 2) lethal cancers (defined as ≥50% 2-year mortality)] in order to meet 
accrual goals for analysis.29 Genomic profiling (GP, Foundation Medicine; 236–405 genes), 
and, if possible, PD-L1 immunohistochemistry (IHC), tumor mutational burden (TMB), 
microsatellite instability (MSI) status, and next generation sequencing (NGS) of blood-
derived circulating tumor DNA (ctDNA) were performed. A Molecular Tumor Board 
discussed results immediately upon receipt and emphasized customized combination 
therapies. The attending physician made final treatment decisions. All analyses were based 
on drugs administered.
Sites and investigator communication: The protocol was conducted at two sites: 
University of California San Diego (UC San Diego) Moores Center for Personalized Cancer 
Therapy and Avera Cancer Institute in Sioux Falls, South Dakota. The study was cross-
institutional in that all investigators, regardless of disease affiliation, at each site could enroll 
patients. Principal investigators and co-investigators, as well as study coordinators reviewed 
information by teleconference (and/or face-to-face meetings for UC San Diego investigators/
coordinators) at least every two weeks. In addition, retreats at the primary site (UC San 
Diego) to review study information occurred at least every two months, with Avera 
physicians and staff teleconferenced in as needed.
Molecular Tumor Board: Molecular Tumor Board face-to-face meetings occurred about 
weekly and were attended by oncologists, surgeons, radiologists, pathologists, basic 
scientists, geneticists, colleagues from the UC San Diego Supercomputer Center, and 
bioinformatics specialists, as well as a medication acquisition specialist and clinical trial 
coordinators/navigators.30,31 In addition, just-in-time (ad hoc) molecular tumor boards 
occurred electronically for any patients whom the physician felt could not wait for the face-
to-face discussion (and for all patients treated at Avera Cancer Institute); patients were 
discussed in this case immediately upon receipt of results. All molecular tumor boards had 
templated information distribution and complied with HIPPA privacy protections 
regulations.
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Next Generation Sequencing, Microsatellite Status (MSI), Tumor Molecular Burden (TMB), 
and PD-L1 Status by Immunohistochemistry
Next generation sequencing (NGS) was performed by Foundation Medicine on tissue and 
blood (FoundationOne™, FoundationOne Heme™ and FoundationACT, Cambridge, 
Massachusetts, http://www.foundationmedicine.com) (CLIA-certified). The 
FoundationOne™ tissue assay utilized during a majority of the study period interrogates 315 
genes, as well as introns of 28 genes involved in rearrangements.32 The current 
FoundationOne Heme™ tissue assay interrogates 406 genes, as well as introns of 31 genes 
involved in rearrangements, as well as sequences RNA of 265 genes commonly rearranged 
in cancer to better identify known and novel gene fusions. Both assays identify all four 
classes of genomic alterations (i.e., base substitutions, insertions and deletions, copy number 
alterations, and rearrangements). All specimens were reviewed by a pathologist to ensure 
specimen viability and tumor content. FoundationACT is a blood-based circulating tumor 
DNA (ctDNA) assay for solid tumors that identifies clinically relevant genomic alterations 
driving the growth of a patient’s cancer.33,34 It interrogates the 62 most clinically-relevant 
cancer genes in solid tumors and is validated to identify all 4 alteration types (base-pair 
substitutions, insertions/deletions, copy-number alterations and rearrangements). Two 
patients in this study only had ctDNA results available.
Microsatellite status (a measure of microsatellite instability, or “MSI”) was determined by 
assessing indel characteristics at 114 homopolymer repeat loci in, or near, the targeted gene 
regions of the FoundationOne assay and was available for N=52 patients. MSI was reported 
as MSI-High, MS-Stable, MSI-Ambiguous, or MSI-Unknown when relevant.
The Foundation Medicine, Inc. Laboratory is Clinical Laboratory Improvement 
Amendments (CLIA) certified. The FoundationOne CDx (F1CDx) is the first U.S. Food and 
Drug Administration (FDA)-approved broad companion diagnostic (CDx). The F1CDx 
Tumor Mutation Burden (TMB) result is pending approval in an expanded CDx claim for 
nivolumab in the front-line setting for non-small cell lung cancer (NSCLC). The TMB 
categorization (into low, intermediate, and high) was assigned as previously described.35 
TMB was defined as the number of somatic, coding, base substitution, and indel mutations 
per megabase of genome examined. All base substitutions and indels in the coding region of 
targeted genes, including synonymous alterations, are initially counted before filtering as 
described below. Synonymous mutations are counted in order to reduce sampling noise. 
While synonymous mutations are not likely to be directly involved in creating 
immunogenicity, their presence is a signal of mutational processes that will also have 
resulted in nonsynonymous mutations and neoantigens elsewhere in the genome. Non-
coding alterations were not counted. Alterations listed as known somatic alterations in 
COSMIC and truncations in tumor suppressor genes were not counted, since our assay genes 
are biased toward genes with functional mutations in cancer.36 Alterations predicted to be 
germline by the somatic-germline-zygosity algorithm were not counted.37 Alterations that 
were recurrently predicted to be germline in our cohort of clinical specimens were not 
counted. Known germline alterations in dbSNP were not counted. Germline alterations 
occurring with two or more counts in the ExAC database were not counted.38 To calculate 
the TMB per megabase, the total number of mutations counted is divided by the size of the 
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coding region of the targeted territory. The nonparametric Mann–Whitney U-test was 
subsequently used to test for significance in difference of means between two populations.”
While germline genomic alterations in mismatch repair (MMR) genes (e.g., MLH1 and 
MSH2) and homology directed repair (HDR) genes (e.g., BRCA1, BRCA2, and ATM), as 
well as bona fide somatic driver alterations were excluded from TMB calculations, they 
were not excluded from use for drug targeting in the patients with ≥1 matched treatment. 
TMB results were reported as follows: TMB-High corresponds to greater than or equal to 20 
mutations per megabase (Muts/Mb); TMB-Intermediate corresponds to 6–19 Muts/Mb; 
TMB-Low corresponds to less than or equal to 5 Muts/Mb. TMB was reported for all 
patients in whom a clinical-grade (CLIA), rather than a research grade, result was available 
since only CLIA results can be used for making treatment decisions for patients in the 
United States.
PD-L1 status (performed by Foundation Medicine) was assessed by immunohistochemistry 
using the U.S. Food and Drug Administration (FDA)-approved Dako 22C3 PD-L1 pharmDx 
qualitative immunohistochemical assay (pre-diluted by manufacturer), which localizes PD-
L1 expression in both tumor cells and tumor-infiltrating immunocytes within formalin-fixed, 
paraffin-embedded (FFPE) tissue sections. Detection was performed using the Ventana 
Optiview DAB detection system on the Ventana Benchmark ULTRA platform. If any of 
these tests had been performed as part of routine physician practice before enrollment, the 
results could be utilized for recommending therapy.
Hormone Receptor Antibodies: The hormone receptor antibody analyses were 
performed as part of standard clinic care at each institution. Estrogen receptor (ER) status 
was assessed by immunohistochemistry using the Ventana ER (SP1) antibody (pre-diluted 
by manufacturer) within FFPE tissue sections and detection was performed using the 
Ventana automated platform at UC San Diego. This test was cleared by the FDA and was 
used per manufacturer’s instructions. ER status was assessed by immunohistochemistry 
using the Dako ID5 ER (1:30 dilution; until 9/2015) and Dako EP1 Ready-To-Use Clone 
(dilution: 1:270; 9/2015–2017) at Avera Cancer Institute. Performance characteristics were 
verified by either UC San Diego and Avera Cancer Institute Departments of Pathology per 
Clinical Laboratory Improvement Amendments (CUA ‘88) requirements and in accordance 
with College of American Pathologists (CAP) checklist requirements and guidance. 
Androgen receptor (AR) status was assessed by immunohistochemistry using the 
CellMarque AR (SP107; dilution 1:100) performed at San Diego Pathology (San Diego, 
CA), a CAP accredited and CLIA certified laboratory facility. A manual platform with 
decloaker with EDTA buffer was utilized for antigen retrieval.
Therapy and Matching
Therapy was recommended by the Molecular Tumor Board, but the actual therapy given was 
the choice of the treating oncologist. Treatment was considered “matched” if at least one 
agent in the treatment regimen targeted at least one aberration, or pathway component, 
altered in a patient’s molecular profile or a protein preferentially expressed in the tumor 
[e.g., estrogen receptor (ER) or androgen receptor (AR) or Her2 status] as assessed by 
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standard of care testing other than NGS, or PD-L1 expression assessed by 
immunohistochemistry as above). For small molecule inhibitors, matching was based on low 
inhibitory concentration 50% (IC50) of the drug for the target (generally, less than 100 nM) 
or for effectors immediately downstream of the gene product altered. Antibodies were 
considered matched if their primary target was the product of the molecular alteration. 
Matching designation was confirmed by the senior investigators (RK and JS), who were 
blinded to patient outcomes at the time of designation. Patients were stratified into those 
having received at least one matched treatment (1 MT) versus no matched treatment (no-
MT) administered, with a later further stratification into those who received treatment with 
Matching Scores >50% versus ≤50%. For patients navigated to a secondary clinical trial, to 
which they consented, the doses used were as per the clinical trial for that cohort. Otherwise, 
dosing combinations of drugs was done according to safety rules gleaned from the literature.
21–24
 If the combination of drugs had established dosing known from clinical trials in the 
literature, that dosing was utilized. If the dosing was unknown, we used data from our 
analyses of almost 75,000 patients treated in the literature21–24 and further modified this 
after discussion in our Molecular Tumor Board and consultation with our PharmD, as 
needed. Essentially, for de novo combinations, we started patients at about 50% of the usual 
dose of each drug for two drug combinations, and at about one-third of the dose of each drug 
for three-drug combinations. Patients then received escalating doses of drug to tolerance, 
while being monitored closely by their treating physicians. Combinations of drugs with 
overlapping toxicities were avoided. The safety of the protocol was also monitored by our 
Data Safety Monitoring Board.
Medication Acquisition Specialist and Clinical Trial Coordinators
In order to obtain medications in a timely fashion, a medication acquisition specialist and 
clinical trial coordinators attended the face-to-face Molecular Tumor Boards. They were 
available immediately upon physician request at other times. Their purpose was to assist 
with obtaining on- and/or off-label approved drugs, as well as information about relevant 
clinical trials utilizing investigational or off-label drugs.
Matching Score
An exploratory scoring system (“Matching Score”) was developed, as previously described.
6,9
 The Matching Score was calculated post hoc by investigators blinded to outcomes at the 
time and it was based upon the actual drugs administered. Under this system, the higher the 
Matching Score, the better the match. In general, the Matching Score was calculated by 
dividing the number of alterations matched in each patient (numerator) by the number of 
characterized aberrations in that patient’s tumor (denominator). For instance, if a patient’s 
tumor harboring six genomic aberrations received two drugs that targeted three of the 
patient’s genomic alterations, the Matching Score would be 3/6 or 50%. This is because 
certain drugs targeted more than one alteration (e.g., many small molecule inhibitors often 
have activity against multiple kinases) and were counted as matches for each identified 
genomic alteration that was matched.
Other considerations were as follows:
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• two mutations in the same gene that had the same effect (e.g., loss of function) 
counted as one aberration in the denominator; two mutations in the same gene 
that were known to function differently counted twice.
• two different structural alterations in the same gene (e.g., amplification and 
mutation) were counted as two aberrations in the denominator since they have 
different functional effects (e.g., overexpression versus activation);
• two drugs targeting the same alteration were counted twice in both the numerator 
and denominator if they had well-established synergy (e.g. the FDA-approved 
combinations of dabrafenib and trametinib for BRAF mutations, or pertuzumab 
and trastuzumab ERBB2 alterations);
• only if the patient was matched (in part) based on hormone (ER) positivity in the 
tissue biopsied for genomic analysis, the ER status was then added to both the 
numerator and the denominator;
• all variants of unknown significance were excluded;
• in the case of cell cycle inhibitors that targeted CDK4/6, we counted any 
concomitant CDK4/6 and CDKN2A/B alterations (N=2 patients) or CCND1/2/3 
and CDKN2A/B alterations (N=2 patients) as one alteration and one drug target 
in the numerator and denominator, because the CDKN2A protein, p16(INK4a), 
directly binds to the CDK4/CDK6/Cyclin D1 complex, thus regulating their 
activity.39,40
• TP53 alterations were considered matched to anti-angiogenic agents, based on 
data showing that TP53 mutations are associated with upregulation of VEGF-A 
and that treatment of TP53-mutant tumors with anti-angiogenic agents is 
associated with improved outcomes.27,28,41,42
• if the patient was treated with immunotherapy (e.g., anti-PD-1 or anti-PD-L1 
checkpoint inhibitors), the Matching Score was 100% for PD-L1 IHC high 
positive, TMB high, MSI high results (or MHL1, MSH2, MSH6, PMS2 
alterations), or if none of the aforementioned were known, but the patient had ≥8 
genomic alterations (N=1 patient) based upon the assumption of a high TMB.
• if PD-L1 IHC was low positive, the TMB was intermediate, or there was a 
CD274 (PD-L1) amplification, the Matching Score was 50%; if the patient 
received a combination of a checkpoint inhibitor and a gene-targeted drug that 
matched one or more of his/her genomic alterations, the score was >50%. As an 
example, if a patient had intermediate TMB and a MET amplification, as well as 
a TP53 mutation, and was treated with nivolumab and the MET inhibitor, 
crizotinib, the Matching Score would be >50%.
• if more than one NGS report was available, the alterations in each report were 
counted (since there can be heterogeneity between tissue biopsies);
• if a patient’s regimen included drugs that did not match any alteration, those 
drugs received a Matching Score of 0.
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The cut-off of 50% for the analyses of low versus high Matching Scores was chosen 
according to the minimum P-value criteria.19 See Supplemental Text for selected examples 
of therapy and Matching Score methodology.
Alternative Approach to Matching Score for Immune Checkpoint Blockade
There may be alternative approaches to scoring matches, especially in the case of 
immunotherapy, as one drug may be used in some circumstances to theoretically target 
multiple genomic alterations. It is becoming increasingly evident that immune checkpoint 
blockade and genomics are not separate silos, but rather linked to each other. This is because 
abnormalities in DNA damage repair and DNA replication can result in increased rates of 
somatic mutations in tumors. In turn, the presentation of neo-antigens generated by the 
mutanome in combination with immune system activation by checkpoint blockade can 
distinguish normal from tumor tissue. Based on studies demonstrating a relationship 
between TMB and immunotherapy response (i.e., the higher the TMB, the greater the 
response rate) and between other gene alterations, such as PDL1 amplification and response, 
genomics is directly relevant to selecting patients for immune checkpoint blockade.17,43 
Furthermore, the FDA has approved the immune checkpoint inhibitor, pembrolizumab, for 
any solid tumor with alterations in DNA mismatch repair pathway genes (e.g.,MSH2, 
MSH6, MLH1, PMS2) due to associated large increases in TMB.35 Moreover, TMB 
increases correlate with a higher neoantigen load based upon somatic mutation data from the 
TCGA.44 In turn, these would be expected to be more immunogenic and therefore 
responsive to immunotherapy.17
In a retrospective fashion that was unblinded to outcomes, we developed an alternative 
approach for scoring immune checkpoint blockade matches. In a histology agnostic fashion, 
we previously reported objective response rates (ORR, %) for patients receiving 
immunotherapy in the setting of low, intermediate, and high TMB.17 Therefore, we adopted 
these ORRs as the matching scores for intermediate TMB (15/48 = 31%) and high TMB 
(22/38 = 58%) tumors. As noted above, four patients (47, 121, 155, A011) had high TMB 
and received immunotherapy, while four more patients (102, 115, A035, A037) had 
intermediate TMB and received immunotherapy. Following evaluation with this alternative 
Matching Score approach, all eight patients remained in their same assigned group with 
Matching Scores >50%. Thus, none of the results changed. Furthermore, if we assessed 
CD274 amplification targeted with immunotherapy as one alterations targeted by one drug, 
the two patients (141, A016) with CD274 amplifications and 11 or 12 other alterations who 
received immunotherapy remained in the Matching Score ≤50% group. Again, the two 
patients’ group assignments did not change with the amended scoring. See Supplemental 
Text for selected examples of immunotherapy and alternative Matching Score methodology.
Response/Outcome Endpoints
All patients were assessed using RECIST version 1.1 by board-certified radiologists at both 
UC San Diego and Avera Cancer Institute. Selected Avera cases were secondarily reviewed 
at UC San Diego. The following radiological endpoints were considered: (i) disease control 
rate (DCR) = rate of [stable disease (SD) ≥6 months + partial response (PR) + complete 
response (CR)] according to RECIST 1.1;45 (ii) progression-free survival (PFS) of therapy 
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given under the I-PREDICT protocol (PFS2); (iii) PFS2 versus PFS1 (immediate prior line 
of therapy using patients as their own control),7,46; (iv) percent of patients with a PFS2/PFS1 
ratio ≥1.3;7 and (v) overall survival (OS). SD, PR, or CR was initially determined per the 
assessment of the treating physician. Patients with ongoing SD for less than six months at 
the date of data cut off were considered inevaluable for the DCR. However, they were 
evaluable for PFS and OS. PFS was defined as the time from the beginning of therapy to 
disease progression, or the time to last follow up for patients that were progression-free 
(patients that were progression-free on the date of last follow up were censored on that date). 
OS was defined as the time from the beginning of therapy to death, or last follow-up date for 
patients who were alive (the latter were censored on that date). The cut-off date of the 
analysis was August 15, 2017 and cut-off date for patients included was consent by end of 
June 2017.
Patients were inevaluable for comparison of PFS on study to prior PFS if prior PFS was for 
therapy given in the adjuvant or neo-adjuvant setting or if prior therapy included a matched 
drug. Patients were considered inevaluable for therapy outcome if: (i) they did not receive 
treatment by 6 months after consent; (ii) patients had not received at least 10 days of therapy 
(if the drug was taken orally); (iii) patients had not received two doses of an intravenous 
drug given once every two weeks or more often; or (iv) patients had received only one dose 
of drug in case of an intravenous drug given every three weeks or less frequently.
Data Collection and Data Analysis
All data was collected in a Microsoft Access 2013 (version 15.0) database. Logistic 
regressions were performed for binary endpoints. Hazard ratios (HR) for the PFS and OS 
were analyzed by the Kaplan-Meier method20 and the log-rank test was used to compare the 
survival endpoints by groups. Cox regression models were used as multivariable analysis 
when appropriate for survival endpoints. The importance of a prognostic factor was assessed 
by the odds ratio (OR) using log-rank test and logistic regression/Cox regression models). 
Statistical analysis was performed by MS and RO, as well as verified by JJL using SPSS 
version 24.0.
Life Sciences Reporting Summary
Additional methodological details can be found in the “Life Sciences Reporting Summary.”
Data Availability
Supporting source data for all figures and tables are made available in Supplementary Table 
1 and Supplementary Table 2.
Extended Data
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Extended Data Figure 1. 
Consolidated Standards of Reporting Trials (CONSORT) diagram, which includes the 149 
patients that consented to I-PREDICT.
* Treated evaluable patients includes patients who received >10 d of treatment for drugs 
given on a daily basis (generally drugs given by mouth) or at least two doses of a drug 
normally given every two weeks or more frequently (the latter generally being intravenous 
drugs). Only patients whose treatment was reviewed and validated by data analysis 
lockdown are included.
** One patient had inadequate tissue for NGS and declined biopsy; he was later reenrolled 
after he agreed to undergo biopsy.
Note: One treated patient who initially was believed to have prior therapy was found, after 
data lockdown analysis, to have not received the prior regimen.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Molecular alterations targeted by matched therapies and impact of the Matching Score 
on treatment outcome.
A. Pie graph of the percentage of actionable aberrations in the indicated targets or target 
pathways for the 73 patients who received at least one matched drug. Since some patients 
had alterations targeted in multiple genes or pathways, the percentages do not add up to 
100%. “Immune checkpoints” refers to amplification of the CD274 (PD-L1) and/or 
PDCD1LG2 (PD-L2) genes, positive PD-L1 expression (immunohistochemistry), high/
intermediate tumor mutational burden, or high microsatellite instability; “MAPK pathway” 
refers to alterations in the KRAS, BRAF, GNAS, MEK1, NF2 or JAK2 genes; “ERBB 
pathway” refers to alterations in the ERBB2 or ERBB3 genes; “PI3K pathway” refers to 
alterations in the AKT1, AKT2, PIK3CA, PIK3R1 or PTEN genes; “FGF/FGFR” pathway 
refers to alterations/amplifications in the FGFR1/2/3, FGF3, FGF4, FGF6, FGF19, FGF23 
or FRS2 genes; “Beta-catenin pathway” refers to alterations in the APC, CTNNB1 or FAT1 
genes; “Cell cycle regulation” refers to alterations in the CDKN2A/B, CCND1/2 or CDK4/6 
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genes; “HGF/MET pathway” refers to alterations in the HGF or MET genes; “BRCA 
complex” refers to alterations in the BRCA1, BRCA2, ATM, BRIP or PALB2 genes; 
Estrogen receptor” refers to alterations in the ESR1 gene or estrogen receptor (ER) positivity 
as assessed by immunohistochemistry; “Other” refers to alterations in the MYC or EWSR1 
genes. TP53, EGFR, PTCH1, and RET refer to alterations in the genes encoding these 
proteins.
B. Pie graph of the percentage of actionable aberrations in the indicated targets or target 
pathways for the 28 patients who had a Matching Score >50%. In these 28 patients, a total of 
67 molecular alterations were matched to treatments.
C. Bar graph analyzing the percentage of patients with SD ≥6 months, partial response (PR), 
and complete response (CR) for patients with a Matching Score of ≤50% (N=49) versus 
>50% (N=20). P-values were computed using a binary logistic regression test.
D. Bar graph analyzing the percentage of patients with a PFS ratio ≥1.3 versus PFS<1.3 for 
patients with a Matching Score of ≤50% (N=49) versus >50% (N=20). P-values were 
computed using a binary logistic regression test.
E. Kaplan-Meier curves display progression-free survival (PFS) for patients with a Matching 
Score ≤50% (N=55) versus >50% (N=28). P-values are from the log-rank test (two-sided)
F. Kaplan-Meier curves display overall survival (OS) for patients with a Matching Score 
≤50% (N=55) versus >50% (N=28). P-values are from the log-rank test (two-sided). 
*Median OS not reached after a median follow up of 8.5 months.
Sicklick et al. Page 21
Nat Med. Author manuscript; available in PMC 2019 October 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sicklick et al. Page 22
Table 1.
Patient demographics, molecular pathology, and treatment history.
Consented patients (N) 149
  Treated patients [N (% of consented patients)] 83 (55.7%)
  Patients with ≥1 matched treatment [N (% of consented patients)] 73 (49.0%)
  Patients with no matched treatments administered [N (% of consented patients)] 10 (6.7%)
Age1 (Median, 95% CI, Range) 62 (59–65, 21–86)
Gender1 [N (%)]
  Women 55 (66.3%)
  Men 28 (33.7%)
Ethnicity1 [N (%)]
  Caucasian 67 (80.7%)
  Asian 4 (4.8%)
  African American 1 (1.2%)
  Other or unknown 11 (13.3%)
Tumor type1 [N (%)]
  Gastrointestinal & hepatopancreatobiliary 35 (42.2%)
  Gynecologic 14 (16.9%)
  Breast 12 (14.5%)
  Central nervous system (CNS) 6 (7.2%)
  Genitourinary 3 (3.6%)
  Head and neck 3 (3.6%)
  Lung 3 (3.6%)
  Other2 7 (8.4%)
Number of total genomic alterations1 (Median, Range; VUS excluded) 5 (1–19)
Number of administered drugs1 (Median, Range) 2 (1–5)
Median number of prior therapies in the metastatic setting1 (Median, IQR) 2 (1–3)
1
Parameters shown are for the 83 treated patients (N=83).
2Other included liposarcoma (N=2); carcinoma of the skin, neuroendocrine carcinoma, fibromyxoid sarcoma, bone marrow multiple myeloma, and 
paraganglioma (N=1 each).
Abbreviations: CI = Confidence Interval; IQR = interquartile range: N=number; VUS = variant of unknown significance.
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